Akèy › Limfom Difize Gwo Selil B
Etid klinik pou Limfom Difize Gwo Selil B ap rekrite nan Etazini
101 etid pou Limfom Difize Gwo Selil B ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Nashville, TN14 etid
- Dallas, TX13 etid
- Seattle, WA12 etid
- Washington, DC12 etid
- Salt Lake City, UT12 etid
- Cleveland, OH11 etid
- Denver, CO11 etid
- Cincinnati, OH11 etid
- Rochester, MN10 etid
- Columbus, OH10 etid
- Richmond, VA10 etid
- Edison, NJ9 etid
- Atlanta, GA9 etid
- Cedar Rapids, IA9 etid
- Omaha, NE9 etid
- Jacksonville, FL8 etid
- Sacramento, CA8 etid
- Grand Rapids, MI8 etid
- Greenburgh, NY8 etid
- San Francisco, CA8 etid
- New Haven, CT8 etid
- San Antonio, TX8 etid
- St. Louis, MO8 etid
- Louisville, KY8 etid
- Indianapolis, IN7 etid
- Aurora, CO7 etid
- Kansas City, MO7 etid
- Charlottesville, VA7 etid
- Miami, FL7 etid
- Buffalo, NY6 etid
Pa eta
- Alabama4 etid
- Arizona13 etid
- Arkansas4 etid
- Colorado19 etid
- Connecticut8 etid
- Distrik Columbia4 etid
- Florid23 etid
- Georgia14 etid
- Idaho4 etid
- Illinois22 etid
- Indiana9 etid
- Iowa11 etid
- Kalifòni43 etid
- Kansas7 etid
- Kentucky11 etid
- Lwizyàn6 etid
- Maryland13 etid
- Massachusetts16 etid
- Michigan15 etid
- Minnesota16 etid
- Missouri8 etid
- Montana4 etid
- Nebraska9 etid
- Nevada3 etid
- New Jersey13 etid
- New Mexico3 etid
- New York31 etid
- North Carolina20 etid
- North Dakota4 etid
- Ohio24 etid
- Oklahoma5 etid
- Oregon16 etid
- Pennsylvania19 etid
- South Carolina4 etid
- South Dakota4 etid
- Tennessee18 etid
- Texas29 etid
- Utah14 etid
- Virginia17 etid
- Washington17 etid
- Wisconsin19 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06977711Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Ap rekriteFaz 2
Laj 65 a 99 · Tout sèks · Mizajou Sep 29, 2026 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT03418038A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06091865A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04002947Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05757219A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06784726Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07365306CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT06687772Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.